Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 177Lung Neoplasms 59Neoplasms 24Neoplasm Metastasis 17Parkinson Disease 4, Autosomal Dominant Lewy Body 13Mesothelioma, Malignant 12Carcinoma 11Colorectal Neoplasms 10Mesothelioma 9Meningeal Carcinomatosis 8Melanoma 7Brain Neoplasms 7Pancreatic Neoplasms 6Adenocarcinoma of Lung 6Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Colonic Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Non-squamous Non-small Cell Lung Cancer 3Neoplasms by Histologic Type 3NSCLC 3Lung Diseases 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Bronchogenic 3Adenocarcinoma 3Thoracic Neoplasms 2

Interventions

Vincristine 1Radiotherapy 1Pemetrexed 1HhAntag691 1Gemcitabine 1Exercise 1Cyclophosphamide 1Craniospinal Irradiation 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infratentorial Neoplasms × Pemetrexed × 1 year × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡